Date: 2014-07-22
Type of information: Capital increase
Company: 3P Biopharmaceuticals (Spain)
Investors: Infarco (Spain)
Amount: € 6 million
Funding type: capital increase
Planned used: This capital increase will allow 3P Biopharmaceuticals to strengthen its staff and infrastructure to meeting the growing demand of its future customer base, consisting mostly of consolidated biotech companies and multinationals from the biopharmaceutical sector.
Others: * On July 22, 2014, 3P Biopharmaceuticals has announced a capital increase of 6 million euros. The operation was carried out through the share ownership of a new partner, the Spanish pharmaceutical group Infarco, which is now the company’s major shareholder. Infarco, meanwhile, undertakes this investment as part of a strategy of diversification and internationalization that will permit it to enter the world of biotechnology.
Therapeutic area: Technology - Services
